论文部分内容阅读
本研究(Dutch Stent Thrombosis Registry)为一项多中心研究,纳入了2004年1月至2007年2月期间经造影确认的ST病例。本研究ST的定义根据ARC分类为明确的血栓形成。根据事件发生的时间分为急性(24 h之内)、亚急性(24h～30 d)、晚期(30 d～1年)和极晚期(1年以后)血栓形成。临床随访采用电话方式询问患者、亲属及家庭医生,或从药房、医院记录获得患者情况。随访内容为主要不良心血管事件(MACE)的发生率(包括死亡、再发ST、心肌梗死和冠状动脉重建术)。研究的一级终点为心源性死亡和明确的再发ST(ARC分类);二级终点为全因死亡、心源性死亡、再发明确的ST、再发明确的或可能的ST、靶血管或非靶血管相关的心肌梗死和任何缺血驱使的靶血管血运重建。共437例患者有明确ST纳入本研究。其中6例因既往曾有ST而被剔除。第1次发生明确ST的431例患者中,140例为急性ST[占总数的32.5%,占金属裸支架(BMS)的33%,占药物洗脱支架(DES)的30%],177例为亚急性ST(占总数
This study, the Dutch Stent Thrombosis Registry, is a multicenter study that included ST-confirmed ST-patterns between January 2004 and February 2007. The definition of ST in this study was categorized according to ARC as definite thrombosis. According to the time of the event, the patients were divided into acute (within 24 h), subacute (from 24 to 30 d), late stage (30 d to 1 year) and very late thrombosis (after 1 year). Clinical follow-up telephone, asking patients, relatives and family doctors, or from the pharmacy, hospital records of patients. Follow-up was defined as the incidence of major adverse cardiovascular events (MACE) including death, recurrent ST, myocardial infarction, and coronary revascularization. The primary end point of the study was cardiogenic death and a clear recurrence of ST (ARC classification); the secondary end point was all-cause death, cardiogenic death, re-definite ST, relapse of definite or probable ST, target Vascular or non-target vessel-related myocardial infarction and any ischemia-driven target revascularization. A total of 437 patients with definite ST were included in this study. Six of these patients were excluded because of previous ST status. Of the 431 patients who developed a definite ST for the first time, 140 were acute ST [32.5% of the total, accounting for 33% of bare metal stents (BMS), accounting for 30% of drug-eluting stents (DES)] and 177 Subacute ST (total number